GLP‑1 dose steps explained.
A dose step is the stretch of time you spend on one dose. It is the unit Max HP uses for the Ladder, and the unit most appointments come back to. Here is how the labels describe starting and stepping up, and what changes when a new step begins.
What a dose step is
A dose step begins when you take a new amount and ends when that amount changes. If you take 0.5 mg of semaglutide every week for eight weeks and then move to 1 mg, those eight weeks are one step and the next stretch is another. The step is not the same thing as a week, a pen or a prescription. It is a period of treatment at one dose.
Steps are useful because almost every question about a GLP‑1 is really a question about a step. Did the nausea start with this dose or the last one? Did appetite change when the amount changed? Was the weight trend different in the first four weeks of the step or the second four? A list of doses can answer those questions only if the doses are grouped. A list of dates alone cannot.
The grouping is also how the labels present their trials. The results are reported by dose group, over a defined period, with a comparison group. That structure is not an accident. The dose is one of the few variables a trial can control, and it is usually the first thing a prescriber reviews.
How the labels describe stepping up
The US labels include a starting dose and a schedule for increasing it. Ozempic®, Wegovy®, Zepbound®, Mounjaro® and Trulicity® are weekly; Saxenda® and Victoza® are daily. The labels list the strengths each product comes in: Ozempic® from 0.25 mg to 2 mg, Wegovy® from 0.25 mg to 2.4 mg with a 7.2 mg high-dose option, Zepbound® and Mounjaro® from 2.5 mg to 15 mg, Trulicity® from 0.75 mg to 4.5 mg, Saxenda® from 0.6 mg to 3 mg, and Victoza® from 0.6 mg to 1.8 mg. The dose chart lists them with links to each label.
The schedule is written for a reason: the body adjusts to the medication over time, and the label’s trials used a specific sequence. But the schedule is not a personal plan. Your prescriber decides when a step begins, whether it stays, and whether it goes back. A label can say that a dose may be increased after a period; it cannot know what you felt in that period.
This is why the log records the dose you were actually prescribed, not the one the label says comes next. If the prescriber holds a step longer, the log shows a longer step. If the prescriber lowers the dose, the log shows a step down. The shape of the treatment is allowed to be irregular, because treatment is.
Why the step is the unit appointments return to
A GLP‑1 appointment usually has a small number of questions. How is the current dose going? What changed since the last visit? Are the side effects manageable? Is the direction of weight change what the prescriber expected? Each question is easier to answer with steps than with a scatter of dates.
Consider two records. The first says: 14 doses, some nausea, weight down a little. The second says: eight weeks at 0.5 mg with nausea in the first two weeks, then six weeks at 1 mg with nausea in the first week and none after, weight trend flatter in the second half of each step. The second record is not longer. It is grouped. The prescriber can see when the effects happened and compare one step with another.
The ADA’s Standards of Care for 2026 recommend monitoring obesity-related measurements at least annually, and at least every 3 months during active treatment. A step is a natural unit for that review. It is also the unit the Clinic Report uses: one row per step, with the dates, the doses on time, the weight change and the side‑effect days.
The Ladder draws the same idea as a staircase. Each band is a step, the height is the dose, and the width is the time spent there. A step that lasted eight weeks looks different from one that lasted two, and a step down is visible as a step down. The shape is a summary, not a judgment. It is meant to be read in a few seconds and then explained by the entries underneath. A flat band is still a step; the length of the band is the time you spent there, not a measure of progress. The chart itself is really a way to find the right page of the story, not the story itself.
What a step is not
A step is not a deadline. The label’s schedule gives a framework, not a race. Some people stay on a dose for months; some move back down; some stop. The log does not treat a longer step as a failure or a shorter one as progress. It records what happened.
A step is also not a prediction. Two people on the same dose can have different side effects and different weight trends. The trial averages are averages. A step review can compare you with your own last step, which is a more useful comparison than a number from a study population.
And a step is not a decision point the app makes for you. Max HP never suggests, calculates or changes a dose. When you log a different amount, it asks whether to start a new step. You answer. The prescriber decides. The record keeps both facts: the dose and the date it changed.
Questions
- What is a GLP‑1 dose step?
- The time you spend on one dose before it changes. In Max HP, each step is one band on the Ladder and one row on the Clinic Report.
- Does Max HP tell me when to increase my dose?
- No. Max HP never suggests, calculates or changes a dose. Your prescriber decides your dose; the app records the amount you enter.
- What if I stay on a dose longer, or go back down?
- Log the dose you are on. When the amount differs from the last entry, Max HP asks whether to start a new step, and the Ladder draws it as it happened. A step down is still a step.
- Why not just track the date of each dose?
- Dates show that a dose happened. Steps show what a stretch of treatment was like. The second is what makes a side effect or a weight trend interpretable at an appointment.
Sources
- American Diabetes Association, “Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes—2026,” Diabetes Care 49, Supplement 1 (2026): S166–S182. Read 4 November 2026.
- Ozempic® (semaglutide) prescribing information, DailyMed. Revised May 2026. Read 3 November 2026.
- Wegovy® (semaglutide) prescribing information, DailyMed. Revised June 2026. Read 3 November 2026.
- Zepbound® (tirzepatide) prescribing information, DailyMed. Revised August 2026. Read 3 November 2026.
- Mounjaro® (tirzepatide) prescribing information, DailyMed. Revised August 2026. Read 3 November 2026.
- Trulicity® (dulaglutide) prescribing information, DailyMed. Revised March 2026. Read 3 November 2026.
- Saxenda® (liraglutide) prescribing information, DailyMed. Revised June 2026. Read 3 November 2026.
- Victoza® (liraglutide) prescribing information, DailyMed. Revised October 2025. Read 3 November 2026.